Gene therapy—is it really a sound investment prospect?
More grounds for optimism on stopping the poison jabs
What are the grounds for optimism on stopping the gene therapy jabs?
First, there is this recent post:
The US FDA is hot on the heels of Novartis’ Kymriah and it’s shoddy manufacturing practices at their Morris Plains facility. Kymriah is a treatment for rare blood cancers known as CAR-T therapy. The active substance is based on Lentiviral Vector Technology and is manufactured by Oxford Biomedica.
Oxford Biomedica also manufactures the AstraZeneca active substance adenovirus vector. Side effects are similar to the Kymriah gene therapy.
Then there is this vote of confidence below,
Keep reading with a 7-day free trial
Subscribe to INSIDE PHARMA to keep reading this post and get 7 days of free access to the full post archives.